This is the complete 2026 guide to ovarian cancer in India — written for women newly diagnosed, family members supporting them, and anyone trying to understand what the modern treatment landscape actually looks like. It covers symptoms, diagnosis, the four stages, surgical and medical treatment, HIPEC and PARP inhibitors, cost in India, recovery, and how to choose the right team.
Whether you have just been told there is a mass on a scan, are looking after a relative diagnosed last week, or are trying to plan a second opinion, this page is built to be read top-to-bottom or jumped to via the table of contents.
On this page
- 1. Quick overview
- 2. Who gets ovarian cancer in India
- 3. The four major types of ovarian cancer
- 4. Risk factors and genetic causes (BRCA, Lynch)
- 5. Symptoms and when to act
- 6. How ovarian cancer is diagnosed
- 7. The four stages explained
- 8. Treatment by stage
- 9. Surgery — what it actually does
- 10. HIPEC and intraperitoneal therapy
- 11. PARP inhibitor maintenance
- 12. Recurrence and second-line treatment
- 13. Recovery and survivorship
- 14. Cost of treatment in India
- 15. Choosing the right specialist
- 16. About Dr. Nishtha Tripathi Patel
- 17. FAQ
Ovarian cancer india complete guide — 1. Quick overview
Ovarian cancer is a malignant tumour arising from cells of the ovary, fallopian tube, or peritoneum. The three major sub-categories (epithelial, germ-cell, sex-cord stromal) behave so differently they are almost separate diseases. Most adult ovarian cancer (over 85%) is high-grade serous epithelial ovarian cancer, and most of the data on this page refers to that subtype unless specified.
The key facts every patient and family should know upfront:
- Early symptoms are vague — most diagnoses happen at Stage 3 or later.
- Surgical completeness at primary surgery is the single strongest predictor of long-term survival.
- Modern treatment combines surgery, platinum-based chemotherapy, HIPEC where appropriate, and PARP inhibitor maintenance.
- BRCA1/2 testing should be done at diagnosis — it changes treatment AND has implications for family members.
- Outcomes vary dramatically between centres. Surgeon and centre volume matter enormously.
2. Who gets ovarian cancer in India
Ovarian cancer is the fourth most common cancer in Indian women and rising. The Indian Council of Medical Research estimates over 47,000 new cases annually, with significant geographic variation. Compared with Western populations, Indian women tend to present at younger ages (median 50s rather than 60s) and at more advanced stages — partly because of delayed diagnosis and partly because hereditary ovarian cancer (BRCA-related) has different age distribution in Indian families.
Lifetime risk for an average-risk Indian woman is approximately 1 in 75. For BRCA1 carriers it rises to 40–60%. For BRCA2 carriers, 15–25%. Lynch syndrome carriers also have meaningfully elevated risk.
3. The four major types of ovarian cancer
Epithelial ovarian cancer (over 85% of cases): arises from cells lining the ovary or fallopian tube. Sub-types include high-grade serous, low-grade serous, clear cell, endometrioid and mucinous. High-grade serous is the most common and most aggressive — and the most likely to be BRCA-related.
Germ-cell tumours (5%): typically in young women, often curable even at advanced stages. Includes dysgerminoma, immature teratoma, yolk sac tumour, embryonal carcinoma.
Sex-cord stromal tumours (5%): includes granulosa cell tumour. May produce hormones, can present at any age.
Borderline ovarian tumours (5%): have malignant features but limited spread potential. Often presents in younger women, fertility preservation is sometimes possible.
4. Risk factors and genetic causes
The strongest risk factors for ovarian cancer in India:
- Family history of ovarian, breast, pancreatic or prostate cancer in close relatives
- Known BRCA1 or BRCA2 mutation
- Lynch syndrome (Hereditary Non-Polyposis Colorectal Cancer)
- Increasing age (peak incidence 50–60s)
- Nulliparity (never having been pregnant)
- Early menarche, late menopause
- Endometriosis (specifically for clear cell and endometrioid sub-types)
Protective factors include pregnancy, breastfeeding, tubal ligation, and oral contraceptive use — though no single factor reduces risk enough to override genetic predisposition.
For a deeper discussion of BRCA testing and what to do with a positive result, see BRCA testing in India.
5. Symptoms and when to act
Ovarian cancer is called the “silent killer” not because it is symptomless but because its symptoms are vague and easily dismissed. The most common early symptoms are:
- Persistent bloating (not just an occasional bloated day)
- Early satiety — feeling full after small meals
- Pelvic or abdominal pain that does not match the menstrual cycle
- Urinating more often without infection
- Unintentional weight loss combined with abdominal swelling (ascites)
- Persistent fatigue
The decision rule: if two or more of these symptoms persist for more than 2–3 weeks, an ultrasound and CA-125 test are warranted. Most causes will be benign — but the small percentage that are not benefit enormously from early-stage diagnosis. See our 10 hidden signs listicle for detail.
6. How ovarian cancer is diagnosed
The diagnostic pathway typically involves:
- Pelvic ultrasound — first-line imaging, can characterise simple from complex masses
- CA-125 tumour marker — supportive but not diagnostic; elevated in many benign conditions too
- HE4 marker and ROMA index — improves specificity when combined with CA-125
- CT or MRI — to assess local extent, lymph node involvement, distant spread
- Tissue diagnosis — by surgical biopsy at primary surgery, or by image-guided biopsy if neoadjuvant chemotherapy is planned
- Multidisciplinary tumour board review — joint discussion before treatment planning
7. The four stages of ovarian cancer
Ovarian cancer is staged using the FIGO 2014 system:
- Stage 1 — confined to the ovaries. 5-year survival 80–90% with proper treatment. See our Stage 1 treatment page.
- Stage 2 — spread to pelvic structures. 5-year survival 50–70%. See our Stage 2 page.
- Stage 3 — spread beyond the pelvis to the peritoneum or retroperitoneal lymph nodes. Most common stage at presentation in India. Median survival 4–5 years with optimal treatment. See Stage 3 with HIPEC.
- Stage 4 — distant spread (lungs, liver parenchyma). Median survival 2–3 years; selected BRCA-positive patients on PARP maintenance significantly longer. See Stage 4 page.
8. Treatment by stage
The treatment pathway depends critically on stage. The simplified framework:
- Stage 1A/B grade 1: Surgical staging alone; close surveillance. Fertility-preserving option for selected young women.
- Stage 1C onwards: Complete surgical staging + 3–6 cycles of adjuvant carboplatin-paclitaxel.
- Stage 2 and 3: Optimal cytoreductive surgery + 6 cycles platinum-based chemotherapy. HIPEC at interval surgery has Level 1 evidence of survival benefit in selected Stage 3 disease.
- Stage 4: Neoadjuvant chemotherapy then interval cytoreductive surgery (if response is good) then completion chemo + maintenance therapy.
Maintenance therapy with PARP inhibitors (olaparib, niraparib, rucaparib) is now standard-of-care for BRCA-mutated and HRD-positive disease across all advanced-stage patients.
9. Surgery — what it actually does
Ovarian cancer surgery is the cornerstone of treatment. The goal is to remove all visible disease — what surgeons call complete cytoreduction (CC-0) or near-complete cytoreduction (CC-1, residual disease under 2.5mm). Surgical completeness directly correlates with survival.
For advanced (Stage 3) disease the operation may include hysterectomy with bilateral salpingo-oophorectomy, omentectomy, lymph node dissection, peritonectomy, splenectomy, bowel resection, and diaphragmatic stripping — performed in a single 6–10 hour operation. This is why fellowship-trained gynaecological oncosurgeons and high-volume centres matter so much. See our cytoreductive surgery page for technical detail.
10. HIPEC and intraperitoneal therapy
HIPEC (Hyperthermic Intraperitoneal Chemotherapy) is heated chemotherapy delivered into the abdominal cavity immediately after surgical removal of visible disease. The temperature (41–43°C) and direct contact target microscopic residual cancer cells that systemic chemotherapy cannot eradicate.
The landmark 2018 New England Journal of Medicine trial by Van Driel et al. demonstrated that adding HIPEC to interval cytoreductive surgery in Stage 3 ovarian cancer extended both progression-free and overall survival by approximately 12 months. HIPEC is now Level 1 evidence in this setting.
HIPEC is NOT appropriate for every patient. Eligibility depends on PCI score (peritoneal cancer index), surgical resectability, performance status, and cancer biology. See our dedicated HIPEC overview, factors affecting HIPEC success, and 7 HIPEC myths debunked.
PIPAC (Pressurised Intraperitoneal Aerosol Chemotherapy) is a newer, repeat-cycle treatment for recurrent peritoneal disease. See PIPAC overview.
11. PARP inhibitor maintenance therapy
PARP inhibitors (poly-ADP-ribose polymerase inhibitors) target the DNA repair machinery that BRCA-mutated and HRD-positive cancer cells depend on. Olaparib, niraparib and rucaparib are the three options available in India.
For first-line maintenance after good response to platinum-based chemotherapy, PARP inhibitors typically extend progression-free survival by 12–18 months, and in BRCA-mutated patients can extend remission by years. Cost ranges from Rs 80,000–3,00,000 per month depending on agent and brand; insurance coverage is improving but pre-authorisation is required.
12. Recurrence and second-line treatment
Despite optimal first-line treatment, most patients with advanced ovarian cancer eventually develop recurrence. Treatment of recurrent disease is classified by platinum-free interval:
- Platinum-sensitive recurrence (over 6 months from last platinum): repeat platinum-based regimens, often combined with bevacizumab, sometimes secondary cytoreductive surgery + PIPAC for selected cases.
- Platinum-resistant recurrence (under 6 months): non-platinum agents (PLD, weekly paclitaxel, topotecan, gemcitabine) +/- bevacizumab.
See our recurrent disease treatment page for detailed protocols.
13. Recovery and survivorship
Recovery from ovarian cancer surgery is staged in months, not weeks. Typical milestones:
- Days 1–3: ICU or high-dependency care
- Days 4–10: Ward recovery, mobilisation, progression to normal diet
- Weeks 2–4: Outpatient follow-up, drain removal if any, adjuvant chemo decision
- Weeks 4–6: Adjuvant chemotherapy starts (if planned)
- Months 4–6: Completion of first-line chemotherapy
- Months 6+: Maintenance therapy in selected patients, surveillance every 3 months for 2 years, then 6-monthly
14. Cost of treatment in India
Total ovarian cancer treatment in India ranges Rs 4–15 lakh depending on stage, surgical complexity, whether HIPEC is added, and whether maintenance therapy is needed. For honest stage-wise breakdown see our dedicated cost transparency page and HIPEC cost page.
Most cashless health insurance policies cover ovarian cancer surgery and chemotherapy under their cancer benefits. Pre-authorisation is required. PMJAY covers eligible patients up to Rs 5 lakh per year.
15. Choosing the right specialist
Three signals to look for:
- Fellowship training in gynaecological oncology — not just general gynaecology, not just general surgical oncology. Specifically gynae-onco fellowship.
- Personal case volume — surgeons who personally perform 25+ complex cancer surgeries annually have measurably better outcomes than those who do 5–10.
- Multidisciplinary support — a centre with weekly tumour board, medical onco + radiation onco + pathology on site, ICU capability, on-site biomarker testing.
16. About Dr. Nishtha Tripathi Patel
Dr. Nishtha Tripathi Patel (MBBS, DGO, DNB, Fellowship in Gynaecological Oncology, ESGO-certified) is a gynaecological oncosurgeon based in Ahmedabad. With 12+ years of fellowship-trained surgical oncology experience, she treats patients across Sterling Hospitals (Sindhubhavan), KD Hospital (Vaishnodevi Circle), and Welcare Speciality Hospital. She has published academic work on ICG-guided peritonectomy, ERAS in CRS+HIPEC, PIPAC, and recurrent ovarian cancer surgical complexity.
To request a consultation or second opinion, WhatsApp +91 76988 00333. See About Dr. Nishtha for full credentials and publications.
Frequently Asked Questions
What is the 5-year survival rate for ovarian cancer in India in 2026?
Stage-specific: Stage 1 above 90%, Stage 2 around 65%, Stage 3 around 45%, Stage 4 around 25%. Outcomes have improved significantly with HIPEC and PARP maintenance therapy over the past decade, particularly for BRCA-mutated patients.
Should I have a hysterectomy if I have a strong family history of ovarian cancer?
Risk-reducing salpingo-oophorectomy (removing both ovaries and tubes) is recommended for BRCA1 carriers by age 35–40, and BRCA2 carriers by 40–45. Hysterectomy is added in selected cases. The discussion is highly individualised.
Is BRCA testing covered by insurance in India?
Coverage varies. Some cancer-specific insurance policies cover BRCA testing when a clear indication exists (diagnosed cancer + family history). PMJAY does not currently cover germline testing routinely. Pre-authorisation is required for most private insurers.
Can ovarian cancer be detected early through screening?
Population-wide screening of low-risk women is not recommended (no test has shown mortality benefit). Women at high genetic risk may undergo targeted surveillance (transvaginal ultrasound + CA-125 every 6 months) but early detection remains difficult — risk-reducing surgery is more effective in BRCA carriers.
How many cycles of chemotherapy will I need?
Standard first-line is 6 cycles of carboplatin-paclitaxel (3-weekly), spread over approximately 18 weeks. Bevacizumab may be added in selected cases. PARP inhibitor maintenance follows for eligible patients.
What happens after the 5-year mark?
Most surveillance schedules continue every 6 months between years 3–5, then annually until year 10. Late recurrences (beyond 5 years) are uncommon but not rare. Ongoing follow-up matters.
Is robotic surgery used for ovarian cancer?
Robotic surgery has a role in selected early-stage ovarian cancer (Stage 1) and fertility-preserving cases. For advanced disease, open cytoreductive surgery remains standard because complex multi-visceral procedures require open access.
Where in Ahmedabad is the most advanced ovarian cancer care?
Tertiary centres with gynaec-oncology fellowship-trained surgeons + multidisciplinary tumour boards + HIPEC capability + on-site biomarker testing. Sterling Sindhubhavan, KD Hospital, and selected other centres meet this bar. See our Sterling page for specifics.
Can I get a second opinion before surgery?
Yes. Share scanned reports on WhatsApp at +91 76988 00333 — Dr. Nishtha reviews and responds within 24–48 hours. Second opinions are free of cost; you don’t have to switch hospitals to obtain one.
How do I know if HIPEC is right for me?
HIPEC eligibility requires: peritoneal disease that can be completely resected, PCI score generally below 20, good performance status, multidisciplinary review. Not every ovarian cancer patient benefits. See 9 factors that affect HIPEC success.
Medical content reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified. For consultations: WhatsApp +91 76988 00333.